MiRacle of MicroRNA-Driven Cancer Nanotherapeutics

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Aug 12

PMID 35954481

Authors

Goknur Kara

Banu Arun

George A Calin

Bulent Ozpolat

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) are non-protein-coding RNA molecules 20-25 nucleotides in length that can suppress the expression of genes involved in numerous physiological processes in cells. Accumulating evidence has shown that dysregulation of miRNA expression is related to the pathogenesis of various human diseases and cancers. Thus, stragegies involving either restoring the expression of tumor suppressor miRNAs or inhibiting overexpressed oncogenic miRNAs hold potential for targeted cancer therapies. However, delivery of miRNAs to tumor tissues is a challenging task. Recent advances in nanotechnology have enabled successful tumor-targeted delivery of miRNA therapeutics through newly designed nanoparticle-based carrier systems. As a result, miRNA therapeutics have entered human clinical trials with promising results, and they are expected to accelerate the transition of miRNAs from the bench to the bedside in the next decade. Here, we present recent perspectives and the newest developments, describing several engineered natural and synthetic novel miRNA nanocarrier formulations and their key in vivo applications and clinical trials.

Citing Articles

Therapeutic Landscape of FOXM1 in Triple-Negative Breast Cancer and Aggressive Solid Cancers.

Dilmac S, Hamurcu Z, Ozpolat B Cancers (Basel). 2024; 16(22).

PMID: 39594778 PMC: 11593102. DOI: 10.3390/cancers16223823.

Revolutionizing cancer therapy: nanoformulation of miRNA-34 - enhancing delivery and efficacy for various cancer immunotherapies: a review.

Fawzy M, Hassan H, Sedky N, Nafie M, Youness R, Fahmy S Nanoscale Adv. 2024; .

PMID: 39309515 PMC: 11414826. DOI: 10.1039/d4na00488d.

Autophagy-associated non-coding RNAs: Unraveling their impact on Parkinson's disease pathogenesis.

Hussain M, Moglad E, Afzal M, Sharma S, Gupta G, Sivaprasad G CNS Neurosci Ther. 2024; 30(5):e14763.

PMID: 38790149 PMC: 11126788. DOI: 10.1111/cns.14763.

A Narrative Review of Preclinical In Vitro Studies Investigating microRNAs in Myocarditis.

Grodzka O, Procyk G, Wrzosek M Curr Issues Mol Biol. 2024; 46(2):1413-1423.

PMID: 38392209 PMC: 10887635. DOI: 10.3390/cimb46020091.

The miR-146b-3p/TNFAIP2 axis regulates cell differentiation in acute myeloid leukaemia.

Lan G, Wu X, Zhao A, Lan J, Guo Q, Wang B Aging (Albany NY). 2024; 16(2):1496-1515.

PMID: 38271140 PMC: 10866442. DOI: 10.18632/aging.205441.

References

Shukla R, Qin B, Cheng K . Peptides used in the delivery of small noncoding RNA. Mol Pharm. 2014; 11(10):3395-408. PMC: 4186677. DOI: 10.1021/mp500426r. View

Nguyen D, Chang S . Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs. Int J Mol Sci. 2017; 19(1). PMC: 5796015. DOI: 10.3390/ijms19010065. View

Henry J, Azevedo-Pouly A, Schmittgen T . MicroRNA replacement therapy for cancer. Pharm Res. 2011; 28(12):3030-42. DOI: 10.1007/s11095-011-0548-9. View

Kara G, Calin G, Ozpolat B . RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 2022; 182:114113. DOI: 10.1016/j.addr.2022.114113. View

Sun Z, Song X, Li X, Su T, Qi S, Qiao R . In vivo multimodality imaging of miRNA-16 iron nanoparticle reversing drug resistance to chemotherapy in a mouse gastric cancer model. Nanoscale. 2014; 6(23):14343-53. DOI: 10.1039/c4nr03003f. View

Yang X, Shang P, Ji J, Malichewe C, Yao Z, Liao J . Hyaluronic Acid-Modified Nanoparticles Self-Assembled from Linoleic Acid-Conjugated Chitosan for the Codelivery of miR34a and Doxorubicin in Resistant Breast Cancer. Mol Pharm. 2021; 19(1):2-17. DOI: 10.1021/acs.molpharmaceut.1c00459. View

Garzon R, Marcucci G, Croce C . Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9(10):775-89. PMC: 3904431. DOI: 10.1038/nrd3179. View

Pecot C, Calin G, Coleman R, Lopez-Berestein G, Sood A . RNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2010; 11(1):59-67. PMC: 3199132. DOI: 10.1038/nrc2966. View

Hanna J, Hossain G, Kocerha J . The Potential for microRNA Therapeutics and Clinical Research. Front Genet. 2019; 10:478. PMC: 6532434. DOI: 10.3389/fgene.2019.00478. View

10.

Slabakova E, Culig Z, Remsik J, Soucek K . Alternative mechanisms of miR-34a regulation in cancer. Cell Death Dis. 2017; 8(10):e3100. PMC: 5682661. DOI: 10.1038/cddis.2017.495. View

11.

Vangijzegem T, Stanicki D, Laurent S . Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics. Expert Opin Drug Deliv. 2018; 16(1):69-78. DOI: 10.1080/17425247.2019.1554647. View

12.

Bhardwaj A, Singh S, Singh A . MicroRNA-based Cancer Therapeutics: Big Hope from Small RNAs. Mol Cell Pharmacol. 2011; 2(5):213-219. PMC: 3031298. DOI: 10.4255/mcpharmacol.10.27. View

13.

Sekhon B, Kamboj S . Inorganic nanomedicine--part 2. Nanomedicine. 2010; 6(5):612-8. DOI: 10.1016/j.nano.2010.04.003. View

14.

Mehta A, Dalle Vedove E, Isert L, Merkel O . Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles. Pharm Res. 2019; 36(9):133. PMC: 7611029. DOI: 10.1007/s11095-019-2665-9. View

15.

Ganju A, Khan S, Hafeez B, Behrman S, Yallapu M, Chauhan S . miRNA nanotherapeutics for cancer. Drug Discov Today. 2016; 22(2):424-432. PMC: 5309208. DOI: 10.1016/j.drudis.2016.10.014. View

16.

Zhang B, Pan X, Cobb G, Anderson T . microRNAs as oncogenes and tumor suppressors. Dev Biol. 2006; 302(1):1-12. DOI: 10.1016/j.ydbio.2006.08.028. View

17.

Friedman R, Farh K, Burge C, Bartel D . Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008; 19(1):92-105. PMC: 2612969. DOI: 10.1101/gr.082701.108. View

18.

Abd-Aziz N, Kamaruzman N, Poh C . Development of MicroRNAs as Potential Therapeutics against Cancer. J Oncol. 2020; 2020:8029721. PMC: 7378626. DOI: 10.1155/2020/8029721. View

19.

Viricel W, Mbarek A, Leblond J . Switchable Lipids: Conformational Change for Fast pH-Triggered Cytoplasmic Delivery. Angew Chem Int Ed Engl. 2015; 54(43):12743-7. DOI: 10.1002/anie.201504661. View

20.

Gonzalez-Aramundiz J, Peleteiro Olmedo M, Gonzalez-Fernandez A, Alonso Fernandez M, Stefania Csaba N . Protamine-based nanoparticles as new antigen delivery systems. Eur J Pharm Biopharm. 2015; 97(Pt A):51-9. DOI: 10.1016/j.ejpb.2015.09.019. View